Skip to main content

Year: 2025

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distribution partner ordering applicators of YCANTH during Q4’24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recently strengthened balance sheet with the November 2024 $42 million public offering – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., March 11, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...

Continue reading

Concrete Pumping Holdings Reports First Quarter Fiscal Year 2025 Results

Announces Extension of Existing Share Repurchase Plan DENVER, March 11, 2025 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company” or “CPH”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., reported financial results for the first quarter ended January 31, 2025. First Quarter Fiscal Year 2025 Summary vs. First Quarter of Fiscal Year 2024 (where applicable)  ● Revenue of $86.4 million compared to $97.7 million.  ● Gross profit of $31.2 million compared to $33.3 million.  ● Income from operations of $3.5 million compared to $1.5 million.  ● Net loss of $2.6 million compared to a net loss of $3.8 million.  ● Net loss attributable to common shareholders was $3.1 million, or $(0.06) per diluted share, compared to a net loss of...

Continue reading

Westrock Coffee Company Reports Fourth Quarter and Full Year 2024 Results and Provides 2025 and 2026 Outlook

LITTLE ROCK, Ark., March 11, 2025 (GLOBE NEWSWIRE) — Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided its outlook for 2025 and 2026. Full Year 2024 Highlights1Consolidated ResultsNet sales were $850.7 million, a decrease of 1.6% Gross profit was $153.8 million, an increase of 10.0% Net loss was $80.3 million compared to a net loss of $34.6 million in fiscal 2023 Consolidated Adjusted EBITDA2 was $47.2 million and included $12.8 million of scale-up costs associated with our Conway Facility, compared to Consolidated Adjusted EBITDA of $45.1 million and no scale-up costs associated with our Conway FacilitySegment ResultsBeverage SolutionsNet sales were $659.4 million, a decrease of 8.8% Segment...

Continue reading

TerraForm Power Operating Fourth Quarter and Full-Year 2024 Results Webcast and Conference Call

Date: Friday, March 14, 2025Time: 2:00 p.m. (Eastern Time) NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — You are invited to participate in TerraForm Power Operating, LLC’s Fourth Quarter and Full-Year 2024 Results Webcast and Conference Call on March 14, 2025 at 2:00 p.m. (Eastern Time) to discuss results and current business initiatives with senior management. These results will be made available on our website at www.terraform.com in the form of audited consolidated financial statements for the years ended December 31, 2024 and 2023 under “Financials” prior to the webcast and conference call. Participants can join by conference call or webcast: Conference Call Please pre-register by conference call clicking here Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. This process will bypass the...

Continue reading

SuRo Capital Corp. Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Invests $54.5 Million in AI Infrastructure in 2024 CoreWeave, Inc., Single Largest Initial Investment in Fund’s History, Files for IPO Net Asset Value of $6.68 Per Share as of December 31, 2024 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. Net assets totaled approximately $157.6 million, or $6.68 per share, at December 31, 2024, as compared to $6.73 per share at September 30, 2024 and $7.99 per share at December 31, 2023. “Since inception, SuRo Capital has served as the public’s gateway to venture capital, offering unique access to some of the world’s most innovative and sought-after private companies before they become publicly traded....

Continue reading

Synchronoss Technologies Reports Fourth Quarter and Full Year 2024 Results

Fourth Quarter Revenue Grew 6.8% Year-Over-Year to $44.2 Million, Including 91% Recurring Revenue GAAP Gross Margin Expands to 69.1%; Adjusted Gross Margin Rises to 79.3% Announced Three-Year Contract Extension with Major U.S. Telecom Provider in December Unveiled Capsyl, a Turn-Key Personal Cloud Solution for Global Operators, in March 2025 BRIDGEWATER, N.J., March 11, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in Personal Cloud platforms, today reported financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter and Recent Operational HighlightsReported total revenue of $44.2 million, driven primarily by 6.0% cloud subscriber growth year-over-year. Quarterly results included net income of $7.9 million,...

Continue reading

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

– Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 – – Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer’s patients expected H2 2026 – LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. “Over the past year, Voyager has significantly advanced our two wholly-owned programs targeting tau, which we view as the most important target in Alzheimer’s disease. Our anti-tau antibody VY7523...

Continue reading

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H’26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H’26 $357.0 million of cash provides runway into 2H’27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements. “We...

Continue reading

High Wire Networks Cancels $10 Million Equity Line of Credit (ELOC)

The Move Minimizes Dilution, and the ELOC is Not Expected to be Necessary Post-Listing BATAVIA, Ill., March 11, 2025 (GLOBE NEWSWIRE) — High Wire Networks, Inc. (OTCQB: HWNI), a leader in managed services and technology solutions, announced the cancellation of its $10 million Equity Line of Credit (ELOC). The ELOC was part of a recent bridge financing package with a single investment fund. Mark Porter, President and CEO of High Wire Networks, stated, “As we look at the needs of our business going forward and the timing of all contemplated events, we feel that the ELOC is not in the best interest of our shareholders, and we do not expect it would be necessary from now on. After a short discussion, it was deemed mutually beneficial to cancel the ELOC on good terms, as we are mindful of dilution. Though it was part of the package,...

Continue reading

Kalmar Begins Sales of the OT2 EV Electric Terminal Tractor

Kalmar OT2 EVKalmar unveiled its third-generation OT2 EV Electric Terminal Tractor—fully designed and built in Kalmar’s Ottawa, Kansas facility—at the 2025 Technology & Maintenance Council Annual Meeting & Transportation Technology Exhibition in Nashville, Tennessee, USA March 10-12.Nashville, TN, March 11, 2025 (GLOBE NEWSWIRE) — Kalmar announces the official start of sales of the Kalmar Ottawa OT2 EV Electric Terminal Tractor (OT2 EV) at the Technology & Maintenance Council’s 2025 Annual Meeting & Transportation Technology Exhibition in Nashville, Tennessee, USA March 10-12, 2025. The OT2 EV represents Kalmar Ottawa’s third-generation electric terminal tractor and is fully designed and built in-house at the company’s Ottawa, Kansas facility. There are four different models available – two specifically...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.